Business, energy, technology, markets and global industry news from Business News Today

uro-oncology

PharmaDeviceNews uro-oncology
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More
Representative image of vial thawing in a clinical preparation setting, illustrating how Ferring Pharmaceuticals’ faster ADSTILADRIN thaw protocol could improve bladder cancer treatment workflow in BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground

FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.

Read More